Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) EBITDA (2019 - 2025)

Historic EBITDA for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$83.1 million.

  • Nurix Therapeutics' EBITDA fell 2851.66% to -$83.1 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$285.7 million, marking a year-over-year decrease of 3409.85%. This contributed to the annual value of -$285.7 million for FY2025, which is 3409.85% down from last year.
  • Latest data reveals that Nurix Therapeutics reported EBITDA of -$83.1 million as of Q4 2025, which was down 2851.66% from -$91.4 million recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' EBITDA ranged from a high of -$24.5 million in Q1 2021 and a low of -$91.4 million during Q3 2025
  • Its 5-year average for EBITDA is -$47.8 million, with a median of -$45.5 million in 2022.
  • As far as peak fluctuations go, Nurix Therapeutics' EBITDA crashed by 9965.23% in 2021, and later soared by 4145.25% in 2023.
  • Quarter analysis of 5 years shows Nurix Therapeutics' EBITDA stood at -$38.0 million in 2021, then fell by 28.29% to -$48.7 million in 2022, then grew by 6.89% to -$45.3 million in 2023, then crashed by 42.62% to -$64.7 million in 2024, then fell by 28.52% to -$83.1 million in 2025.
  • Its last three reported values are -$83.1 million in Q4 2025, -$91.4 million for Q3 2025, and -$48.3 million during Q2 2025.